EXTON, Pa., April 12 /PRNewswire-FirstCall/ -- Kensey Nash Corporation today announced that it will release its earnings results for its third quarter ended March 31, 2006, at 8:00 a.m. Eastern Time on Monday, April 24, 2006.
Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Monday, April 24, 2006 at 9:00 A.M. Eastern Time.
To participate in the teleconference call, dial 1-612-332-0107. The teleconference call will also be available for replay starting Monday, April 24, 2006 at 12:30 P.M. Eastern Time through Monday, May 1, 2006 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 825913.
Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com. To listen to the live teleconference call, please go to the http://www.kenseynash.com website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com website and may be accessed following the teleconference.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. Many of the products are based on the Company’s significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Recently, the Company has created an endovascular division to launch its novel TriActiv(R) Embolic Protection System, a device designed to prevent debris from traveling downstream from the treatment site during stenting procedures. Kensey Nash is commercializing several versions of the device including TriActiv FX(R) and TriActiv(R) ProGuard(TM) Systems and is also planning to launch the ThromCat(TM) Thrombectomy System and QuickCat(TM) Extraction Catheter as new endovascular products. Kensey Nash is also known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Kensey Nash Corporation
CONTACT: Joseph W. Kaufmann, President and Chief Executive Officer, KenseyNash Corporation, +1-484-713-2100
Web site: http://www.kenseynash.com//
